Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

PI3K/AKT pathway-mediated regulation of p27Kip1 is associated with cell cycle arrest and apoptosis in cervical cancer

(2015) Shyam Babu Prasad et al.   CELLULAR ONCOLOGY

Personalized cancer medicine: next steps in the genomic era

(2015) S. Derks et al.   CELLULAR ONCOLOGY

Epigenetic Silencing of CRABP2 and MX1 in Head and Neck Tumors

(2015) Marilia F. Calmon et al.   NEOPLASIA

T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness

(2014) F. Pinto et al.   CLINICAL CANCER RESEARCH

EGF receptor family: twisting targets for improved cancer therapies

(2014) Antony W. Burgess et al.   GROWTH FACTORS

EGFR signaling patterns are regulated by its different ligands

(2014) Stine Louise Jeppe Knudsen et al.   GROWTH FACTORS

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

(2014) Jian Zhang et al.   Journal of Hematology & Oncology

CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance

(2014) Julieta Afonso et al.   MOLECULAR CARCINOGENESIS

KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy

(2014) L.S. YAMANE et al.   ONCOLOGY REPORTS

In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas

(2014) Olga Martinho et al.   Translational Oncology

Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic

(2014) Ludmila Prudkin et al.   CELLULAR ONCOLOGY

Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

(2013) B. S. Paugh et al.   CANCER RESEARCH

Afatinib: First Global Approval

(2013) Rosselle T. Dungo et al.   DRUGS

Differential sensitivities to lactate transport inhibitors of breast cancer cell lines

(2013) Filipa Morais-Santos et al.   ENDOCRINE-RELATED CANCER

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

(2013) Athanassios Argiris et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASMutation: Should We Test for It, and Does It Matter?

(2013) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation

(2013) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

RKIP Inhibition in Cervical Cancer Is Associated with Higher Tumor Aggressive Behavior and Resistance to Cisplatin Therapy

(2013) Olga Martinho et al.   PLoS One

The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis

(2013) Zi-Xu Yuan et al.   PLoS One

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)

(2013) Kunihiko Kobayashi et al.   Targeted Oncology

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

(2012) Nancy U. Lin et al.   BREAST CANCER RESEARCH AND TREATMENT

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

(2012) Sai-Hong Ignatius Ou   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation

(2012) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

HPV16 Oncoproteins Induce MMPs/RECK-TIMP-2 Imbalance in Primary Keratinocytes: Possible Implications in Cervical Carcinogenesis

(2012) Laura Beatriz da Silva Cardeal et al.   PLoS One

Antiproliferative Effects of Fluoxetine on Colon Cancer Cells and in a Colonic Carcinogen Mouse Model

(2012) Vinicius Kannen et al.   PLoS One

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target

(2011) K Iida et al.   BRITISH JOURNAL OF CANCER

EGFR expression in advanced head and neck cutaneous squamous cell carcinoma

(2011) Larissa Sweeny et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts

(2011) Patrick T. Hennessey et al.   PLoS One

AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

(2011) Hua Xie et al.   PLoS One

Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma

(2010) B. M. Costa et al.   CANCER RESEARCH

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

(2010) Ming-Sound Tsao et al.   Journal of Thoracic Oncology

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

(2010) K. Takezawa et al.   MOLECULAR CANCER THERAPEUTICS

Novel Primate-Specific Genes, RMEL 1, 2 and 3, with Highly Restricted Expression in Melanoma, Assessed by New Data Mining Tool

(2010) Josane F. Sousa et al.   PLoS One

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

(2009) G E Konecny et al.   BRITISH JOURNAL OF CANCER

EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

(2009) D. A. Bax et al.   CLINICAL CANCER RESEARCH

Low frequency of MAP kinase pathway alterations inKITandPDGFRAwild-type GISTs

(2009) Olga Martinho et al.   HISTOPATHOLOGY

The EGFRvIII variant in glioblastoma multiforme

(2009) Hui K. Gan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

(2009) Salvatore Siena et al.   JNCI-Journal of the National Cancer Institute

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development

(2009) Dorine A. Bax et al.   PLoS One

Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context

(2008) Massimiliano Monticone et al.   Molecular Cancer

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE